{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:47:34Z","timestamp":1769755654400,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,29]]},"DOI":"10.7759\/cureus.102562","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:42:50Z","timestamp":1769701370000},"source":"Crossref","is-referenced-by-count":0,"title":["Invasive Pulmonary Aspergillosis in a Young Adult With Hyperimmunoglobulin E Syndrome and Hypogammaglobulinemia Following Rituximab Therapy"],"prefix":"10.7759","author":[{"given":"Gautam K","family":"Pandrangi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritika N","family":"Golechha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Logan R","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Helmstetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073687","article-title":"STAT3 mutations in the hyper-IgE syndrome","volume":"357","author":"Holland SM","year":"2007","unstructured":"Holland SM, DeLeo FR, Elloumi HZ, et al.. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007, 357:1608-19. 10.1056\/NEJMoa073687","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nature06096","article-title":"Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome","volume":"448","author":"Minegishi Y","year":"2007","unstructured":"Minegishi Y, Saito M, Tsuchiya S, et al.. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007, 448:1058-62. 10.1038\/nature06096","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nature06764","article-title":"Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome","volume":"452","author":"Milner JD","year":"2008","unstructured":"Milner JD, Brenchley JM, Laurence A, et al.. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008, 452:773-6. 10.1038\/nature06764","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla FA","year":"2015","unstructured":"Bonilla FA, Khan DA, Ballas ZK, et al.. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015, 136:1186-205. 10.1016\/j.jaci.2015.04.049","journal-title":"J Allergy Clin Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03749-6","article-title":"Pulmonary features and stage of disease in adult patients with hyper-IgE syndrome: a single-centre clinical study and literature review","volume":"20","author":"Xie T","year":"2025","unstructured":"Xie T, Xu N, Zhao H, et al.. Pulmonary features and stage of disease in adult patients with hyper-IgE syndrome: a single-centre clinical study and literature review. Orphanet J Rare Dis. 2025, 20:270. 10.1186\/s13023-025-03749-6","journal-title":"Orphanet J Rare Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01228-5","article-title":"A systematic review regarding the prevalence of malignancy in patients with the hyper-IgE syndrome","volume":"23","author":"Mohammadi T","year":"2023","unstructured":"Mohammadi T, Azizi G, Rafiemanesh H, Farahani P, Nirouei M, Tavakol M. A systematic review regarding the prevalence of malignancy in patients with the hyper-IgE syndrome. Clin Exp Med. 2023, 23:4835-59. 10.1007\/s10238-023-01228-5","journal-title":"Clin Exp Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-010-9452-z","article-title":"Diffuse large B cell lymphoma in hyper-IgE syndrome due to STAT3 mutation","volume":"30","author":"Kum\u00e1novics A","year":"2010","unstructured":"Kum\u00e1novics A, Perkins SL, Gilbert H, Cessna MH, Augustine NH, Hill HR. Diffuse large B cell lymphoma in hyper-IgE syndrome due to STAT3 mutation. J Clin Immunol. 2010, 30:886-93. 10.1007\/s10875-010-9452-z","journal-title":"J Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler S","year":"2018","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018, 1:e184169. 10.1001\/jamanetworkopen.2018.4169","journal-title":"JAMA Netw Open"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00626","article-title":"Immunoglobulin replacement therapy in secondary hypogammaglobulinemia","volume":"5","author":"Compagno N","year":"2014","unstructured":"Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol. 2014, 5:626. 10.3389\/fimmu.2014.00626","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.23435","article-title":"STAT3 and the hyper-IgE syndrome: clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties","volume":"2","author":"Mogensen TH","year":"2013","unstructured":"Mogensen TH. STAT3 and the hyper-IgE syndrome: clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. JAKSTAT. 2013, 2:e23435. 10.4161\/jkst.23435","journal-title":"JAKSTAT"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0094-3","article-title":"Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review","volume":"73","author":"Lingman-Framme J","year":"2013","unstructured":"Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs. 2013, 73:1307-19. 10.1007\/s40265-013-0094-3","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.04.001","article-title":"Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia","volume":"166-167","author":"Spadaro G","year":"2016","unstructured":"Spadaro G, Pecoraro A, De Renzo A, Della Pepa R, Genovese A. Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia. Clin Immunol. 2016, 166-167:103-4. 10.1016\/j.clim.2016.04.001","journal-title":"Clin Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00001011","article-title":"Pulmonary aspergillosis: a clinical review","volume":"20","author":"Kousha M","year":"2011","unstructured":"Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. Eur Respir Rev. 2011, 20:156-74. 10.1183\/09059180.00001011","journal-title":"Eur Respir Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/jof11090617","article-title":"Pulmonary aspergillosis in immunocompromised critically ill patients: prevalence, risk factors, clinical features and diagnosis\u2014a narrative review","volume":"11","author":"Bocci MG","year":"2025","unstructured":"Bocci MG, Cascarano L, Capecchi G, et al.. Pulmonary aspergillosis in immunocompromised critically ill patients: prevalence, risk factors, clinical features and diagnosis\u2014a narrative review. J Fungi (Basel). 2025, 11:10.3390\/jof11090617","journal-title":"J Fungi (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200704-606OC","article-title":"Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients","volume":"177","author":"Meersseman W","year":"2008","unstructured":"Meersseman W, Lagrou K, Maertens J, et al.. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008, 177:27-34. 10.1164\/rccm.200704-606OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson TF","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, et al.. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016, 63:e1-e60. 10.1093\/cid\/ciw326","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202410-2045ST","article-title":"Treatment of invasive pulmonary aspergillosis and preventive and empirical therapy for invasive candidiasis in adult pulmonary and critical care patients: an official American Thoracic Society clinical practice guideline","volume":"211","author":"Epelbaum O","year":"2025","unstructured":"Epelbaum O, Marinelli T, Haydour Q, et al.. Treatment of invasive pulmonary aspergillosis and preventive and empirical therapy for invasive candidiasis in adult pulmonary and critical care patients: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2025, 211:34-53. 10.1164\/rccm.202410-2045ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Baden LR","year":"2016","unstructured":"Baden LR, Swaminathan S, Angarone M, et al.. Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016, 14:882-913. 10.6004\/jnccn.2016.0093","journal-title":"J Natl Compr Canc Netw"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo Y","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018, 9:1299. 10.3389\/fimmu.2018.01299","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14410","article-title":"Alternative pneumocystis pneumonia prophylaxis in solid organ transplants","volume":"27","author":"He KD","year":"2025","unstructured":"He KD, Nguyen L, Norris M, et al.. Alternative pneumocystis pneumonia prophylaxis in solid organ transplants. Transpl Infect Dis. 2025, 27:e14410. 10.1111\/tid.14410","journal-title":"Transpl Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/456911-invasive-pulmonary-aspergillosis-in-a-young-adult-with-hyperimmunoglobulin-e-syndrome-and-hypogammaglobulinemia-following-rituximab-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:42:50Z","timestamp":1769701370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/456911-invasive-pulmonary-aspergillosis-in-a-young-adult-with-hyperimmunoglobulin-e-syndrome-and-hypogammaglobulinemia-following-rituximab-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.102562","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}